Serum selenium levels and the risk of progression of laryngeal cancer

Lubiński, J; Marciniak, Wojciech; Muszyńska, Magdalena; Jaworowska, Ewa; Sulikowski, M; Jakubowska, Anna; Kaczmarek, Katarzyna; Sukiennicki, Grzegorz; Falco, Michał; Baszuk, Piotr; Mojsiewicz, Magdalena; Kotsopoulos, Joanne; Sun, Ping; Narod, Steven A.; Lubiński, Jan

doi:10.1371/journal.pone.0184873

Cited by 27 publications

(23 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, several studies reported an inverse relationship between selenium levels and cancer risk. Recently, Lubiński et al (2018) highlighted that in laryngeal cancer patients, the selenium level at the time of diagnosis was associated with the outcome [ 9 ]; similarly selenium supplementation in women undergoing treatment for breast cancer can favorably influence the patients’ outcomes [ 10 ]. Recently, two reviews highlighted the association between single selenoproteins and either colorectal or prostate cancer initiation and progression, as well as patient outcome, suggesting that these proteins could represent potential biomarkers or therapeutic targets [ 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Integrated Analysis to Study the Relationship between Tumor-Associated Selenoproteins: Focus on Prostate Cancer

Capone

Polo

Sorice

et al. 2020

IJMS

View full text Add to dashboard Cite

Selenoproteins are proteins that contain selenium within selenocysteine residues. To date, twenty-five mammalian selenoproteins have been identified; however, the functions of nearly half of these selenoproteins are unknown. Although alterations in selenoprotein expression and function have been suggested to play a role in cancer development and progression, few detailed studies have been carried out in this field. Network analyses and data mining of publicly available datasets on gene expression levels in different cancers, and the correlations with patient outcome, represent important tools to study the correlation between selenoproteins and other proteins present in the human interactome, and to determine whether altered selenoprotein expression is cancer type-specific, and/or correlated with cancer patient prognosis. Therefore, in the present study, we used bioinformatics approaches to (i) build up the network of interactions between twenty-five selenoproteins and identify the most inter-correlated proteins/genes, which are named HUB nodes; and (ii) analyze the correlation between selenoprotein gene expression and patient outcome in ten solid tumors. Then, considering the need to confirm by experimental approaches the correlations suggested by the bioinformatics analyses, we decided to evaluate the gene expression levels of the twenty-five selenoproteins and six HUB nodes in androgen receptor-positive (22RV1 and LNCaP) and androgen receptor–negative (DU145 and PC3) cell lines, compared to human nontransformed, and differentiated, prostate epithelial cells (EPN) by RT-qPCR analysis. This analysis confirmed that the combined evaluation of some selenoproteins and HUB nodes could have prognostic value and may improve patient outcome predictions.

show abstract

Section: Introductionmentioning

confidence: 99%

Integrated Analysis to Study the Relationship between Tumor-Associated Selenoproteins: Focus on Prostate Cancer

Capone

Polo

Sorice

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Serum selenium, iron, zinc, and copper levels were quantified by inductively coupled mass spectroscopy (ICP-MS NexION 350D, PerkinElmer) using methane to reduce polyatomic interferences, following Lubinski et al [20,21]. Calibration standards were prepared by diluting 10 mg/L Multi-Element Calibration Standard 3 (PerkinElmer Pure Plus, PerkinElmer Life and Analytical Sciences, USA) with a blank reagent consisting of a 0.65% solution of nitric acid (Merck, Germany) and 0.002% Tryton X-100 (PerkinElmer, USA).…”

Section: Element Assaymentioning

confidence: 99%

“…Another bioelement, selenium (Se), also affects redox status on account of its antioxidative properties [8,23]. Notably, it can be used as a cancer marker [20,21]. According to the statistics, transplant recipients are highrisk cancer patients [4,5,37].…”

Section: Introductionmentioning

confidence: 99%

Serum Selenium, Iron, Zinc, and Copper Concentrations in Renal Transplant Recipients Treated with Mycophenolate Mofetil

Wilk

Szypulska-Koziarska

Marchelek-Myśliwiec

et al. 2020

Biol Trace Elem Res

View full text Add to dashboard Cite

There are data available in the literature on bioelement concentrations in the serum of various groups of patients; however, very little is known about the serum concentration of selenium (Se), iron (Fe), zinc (Zn), and copper (Cu) in renal transplant patients treated with immunosuppressive drugs, including mycophenolate mofetil (MMF). Monitoring of serum bioelement concentrations in renal transplant recipients is of profound importance, as the proper bioelement levels seem to prolong the normal function of the transplanted organ. Thus, the aim of this current study was to examine and carry out comparative analysis involving serum concentrations of Se, Fe, Cu, and Zn of renal transplant recipients treated with MMF and without MMF. The material consisted of blood samples from 115 patients of the the city of Szczecin in the northwestern Poland. Serum Se, Fe, Cu, and Zn levels were quantified by inductively coupled mass spectroscopy (ICP-MS). Taking into account all patients, MMF increases Cu level. Cu and Fe concentrations were significantly higher in women treated with MMF; in group of younger patients treated with MMF, Se level was significantly lower comparing with those whose regimen did not include MMF. Additionally, MMF in combination with prednisone increased Se concentration in blood of transplant recipients. Our study highlights that trace elements should be monitored to allow for an early detection of trace elements deficits, which can easily be corrected for by an adjusted diet or supplemental intake.

show abstract

“…In einer weiteren Beobachtungsstudie aus Polen zeigten sich vergleichbare Daten bei Patienten mit Larynxkarzinomen [93].…”

Section: Hno-tumorenunclassified

Mikronährstoffe in der Onkologie: Risiko und Nutzen – Update 2020

Mücke

Micke

Büntzel

et al. 2020

TumorDiagnostik & Therapie

View full text Add to dashboard Cite

Zusammenfassung Hintergrund Das Interesse sowohl von betreuenden Ärzten als auch Tumorpatienten an der zusätzlichen Einnahme von Mikronährstoffen während einer onkologischen Therapie mit unterschiedlichen Intentionen nimmt zu. Dieses Update liefert deshalb eine Standortbestimmung zum zusätzlichen Einsatz von ausgewählten Mikronährstoffen während der Tumortherapie. Methoden Es wurde eine Literaturrecherche hinsichtlich des Einsatzes von ausgewählten Mikronährstoffen in der Onkologie, die bis 2018 in zitierfähigen Journalen erschienen sind, durchgeführt. Ergebnisse Daten zu Mikronährstoffen, die sowohl hinsichtlich der Lebensqualität als auch der Prognose einen Nutzen für onkologische Patienten bringen, als auch Erkenntnisse zu Mikronährstoffen, die für die Patienten keinen Benefit haben oder sogar schaden, werden präsentiert. Die gute Datenlage hinsichtlich Vitamin D und Selen erlaubt hier die Empfehlung zur Supplementation nach Spiegelbestimmung im Serum. Schlussfolgerung Nicht nur vorrangig onkologisch tätige Ärzte, sondern auch alle Ärzte, die Tumorpatienten mitbetreuen, sollten Kenntnisse über die wichtigsten Mikronährstoffe haben, um diese an die Patienten weiterzugeben und sie auch gezielt zum Nutzen der Patienten einzusetzen.

show abstract

Serum selenium levels and the risk of progression of laryngeal cancer

Cited by 27 publications

References 33 publications

Integrated Analysis to Study the Relationship between Tumor-Associated Selenoproteins: Focus on Prostate Cancer

Integrated Analysis to Study the Relationship between Tumor-Associated Selenoproteins: Focus on Prostate Cancer

Serum Selenium, Iron, Zinc, and Copper Concentrations in Renal Transplant Recipients Treated with Mycophenolate Mofetil

Mikronährstoffe in der Onkologie: Risiko und Nutzen – Update 2020

Contact Info

Product

Resources

About